Authorized purpose: Provides CADe/CADx for compatible DBT examinations by marking breast masses, distortions/asymmetries, and calcifications for concurrent physician interpretation.
Clinical role
Concurrent reading aid that marks soft tissue densities and calcifications on DBT exams with confidence scores and a case score, sent as a DICOM CAD SR object to review workstations; the interpreting physician confirms or dismisses each finding.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Use is constrained to specified compatible systems and slice types, and the physician confirms or dismisses findings.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provides CADe/CADx for compatible DBT examinations by marking breast masses, distortions/asymmetries, and calcifications for concurrent physician interpretation.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Specified Hologic Selenia Dimensions or 3Dimensions DBT slices.
Who uses it?Intended users: MQSA-qualified interpreting physicians and radiologists.
What does the software produce?Output: DICOM MammographyCAD SR with lesion location, outline, confidence, case score, and CC-MLO correlation.
What is its most important limitation?Key limitation: Use is constrained to specified compatible systems and slice types, and the physician confirms or dismisses findings.
Clinical takeaway. Clinical role: Provides CADe/CADx for compatible DBT examinations by marking breast masses, distortions/asymmetries, and calcifications for concurrent physician interpretation.
Evidence takeaway. Evidence from the reviewed source record: Standalone evaluation included 106 biopsy-proven malignant cases and 561 screening-negative cases (667 total), with 239 truth marks and 113 truth pairs; final numeric accuracy was not reported.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provides CADe/CADx for compatible DBT examinations by marking breast masses, distortions/asymmetries, and calcifications for concurrent physician interpretation.
Exact FDA submission
Checked 2026-09-15
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Concurrent reading aid that marks soft tissue densities and calcifications on DBT exams with confidence scores and a case score, sent as a DICOM CAD SR object to review workstations; the interpreting physician confirms or dismisses each finding.
Exact FDA submission
Checked 2026-11-14
Packet wording: "to identify and mark regions of interest including soft tissue densities (masses, architectural distortions and asymmetries) and calcifications in DBT exams from compatible DBT systems and provide confidence scores that offer assessment for Certainty of Findings and a Case Score." … "The device intends to aid in the interpretation of digital breast tomosynthesis exams in a concurrent fashion, where the interpreting physician confirms or dismisses the findings during the reading of the exam.". Read from the exact FDA decision document on 2026-11-14.
Standalone evaluation included 106 biopsy-proven malignant cases and 561 screening-negative cases (667 total), with 239 truth marks and 113 truth pairs; final numeric accuracy was not reported.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Standalone evaluation included 106 biopsy-proven malignant cases and 561 screening-negative cases (667 total), with 239 truth marks and 113 truth pairs; final numeric accuracy was not reported.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Genius AI Detection 2.0 with CC-MLO Correlation regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K230096
Samplen=667
IndependenceIndependence not established
K230096
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K230096. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Specified Hologic Selenia Dimensions or 3Dimensions DBT slices.
Scope: Exact FDA submission. Exact compatible systems and slice types.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes Genius AI Detection packaging its CAD findings into a DICOM Mammography CAD SR object and distributing it for display on DICOM compliant review workstations. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "Genius AI Detection packages all CAD findings derived from the corresponding analysis of a tomosynthesis exam into a DICOM Mammography CAD SR object and distributes it for display on DICOM compliant review workstations.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the deployment of Genius AI Detection 2.0 with CC-MLO Correlation as a stand-alone computer, with a softcopy workstation as the output device, the same as the predicates. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Output Device Softcopy Workstation Same Same N/A Deployment Stand-alone computer Same Same N/A" … "Features and Subject Device Predicate Difference and Characteristics Hologic, Inc. Hologic, Inc. ScreenPoint comments". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: DICOM MammographyCAD SR with lesion location, outline, confidence, case score, and CC-MLO correlation.
Scope: Exact FDA submission. FDA output description.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the deployment of Genius AI Detection 2.0 with CC-MLO Correlation as a stand-alone computer, with a softcopy workstation as the output device, the same as the predicates. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Output Device Softcopy Workstation Same Same N/A Deployment Stand-alone computer Same Same N/A" … "Features and Subject Device Predicate Difference and Characteristics Hologic, Inc. Hologic, Inc. ScreenPoint comments". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes Genius AI Detection packaging its CAD findings into a DICOM Mammography CAD SR object and distributing it for display on DICOM compliant review workstations. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Genius AI Detection packages all CAD findings derived from the corresponding analysis of a tomosynthesis exam into a DICOM Mammography CAD SR object and distributes it for display on DICOM compliant review workstations.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Hologic's Breast and Skeletal Products Cybersecurity page states patch validation for Hologic Breast and Skeletal Health systems, MDS2 forms availability, and published security advisories with product impact analyses (including Libwebp, MOVEit, Log4j and Axeda advisories).
Product family
Checked 2026-10-26
Vendor statement, not an attestation. Page scope is Hologic's Breast and Skeletal Health division; this entry is a mammography/DBT product within that division. Exact-release scope is not established.
Hologic's Breast & Skeletal Products cybersecurity page states that it provides validated patches, MDS2 forms and security advisories with product impact analyses, with published advisories covering Libwebp, MOVEit, Log4j and Axeda.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page scopes to Hologic Breast & Skeletal products generally and does not scope this process to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Genius AI Detection 2.0 with CC-MLO Correlation; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not yet reviewed - checked 2026-08-31 - Exact FDA submission
Confirm the intended care setting, patient population, and service line.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K230096 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.